Failed to pulmonary treatment GlaxoSmithKline
September 8 (Reuters) - GlaxoSmithKline Pharmaceutical company and its partner Theravance announced Tuesday the failure of treatment by inhalation Breo prolong the life of patients with chronic respiratory diseases cause many deaths through the world.
The Theravance stock has plunged 14% at the NYSE on the announcement of the failure of this clinical trial on 16,500 people.The action listed in New York Glaxo , a significantly larger laboratory , has instead taken 2.2%, but slightly less than the major indices on Wall Street.Investors hoped that success in these large trials would inflate significantly the sales of this treatment.This drug was approved in 2013 to treat chronic obstructive pulmonary disease , often called smoker's cough .If clinical trials were inconclusive, the Breo would become the first treatment to allow an extension of the life of people with this disease.
